argenex (NASDAQ:ARGX) Stock Gets Price Target Cut from Guggenheim

Key Points

• Guggenheim cut argenx’s price target from $1,185 to $1,120 while maintaining a “Buy” rating, implying approximately 28.75% upside from the reported share price.
• Despite the reduction, analyst sentiment remains favorable: argenx has a consensus “Moderate Buy” rating and an average price target of $1,145.53.
• argenx reported quarterly EPS of $7.80, beating estimates of $7.44, on revenue of approximately $1.75 billion. Shares traded at $869.87, while a setback in a VYVGART-related Sjögren’s syndrome study raised concerns about pipeline expansion.

argenex (NASDAQ:ARGX - Get Free Report) had its target price reduced by equities researchers at Guggenheim from $1,185.00 to $1,120.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price target would indicate a potential upside of 28.75% from the company's current price.

Several other brokerages have also weighed in on ARGX. Bank of America lifted their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the company a "buy" rating in a research report on Thursday, July 2nd. DZ Bank reissued a "buy" rating on shares of argenex in a research report on Friday, October 9th. Citigroup increased their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. The Goldman Sachs Group restated a "buy" rating on shares of argenex in a research note on Friday, September 25th. Finally, Sanford C. Bernstein reaffirmed a "buy" rating on shares of argenex in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,145.53.

argenex Price Performance

Shares of NASDAQ ARGX traded down $5.89 during trading hours on Friday, reaching $869.87. The stock had a trading volume of 89,926 shares, compared to its average volume of 351,696. The company has a market cap of $54.71 billion, a price-to-earnings ratio of 33.37, a PEG ratio of 0.82 and a beta of 0.44. argenex has a twelve month low of $661.85 and a twelve month high of $1,072.75. The business's fifty day moving average is $956.17 and its two-hundred day moving average is $885.45.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a net margin of 32.19% and a return on equity of 43.59%. The firm had revenue of $1.75 billion for the quarter. Sell-side analysts forecast that argenex will post 28.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenex

Institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company's stock worth $1,847,592,000 after buying an additional 83,568 shares during the last quarter. Jennison Associates LLC raised its stake in shares of argenex by 3.4% in the first quarter. Jennison Associates LLC now owns 237,468 shares of the company's stock valued at $173,411,000 after acquiring an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of argenex by 1.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company's stock valued at $130,277,000 after acquiring an additional 2,579 shares during the last quarter. First Trust Advisors LP raised its stake in shares of argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company's stock valued at $78,279,000 after acquiring an additional 53,293 shares during the last quarter. Finally, Eagle Health Investments LP boosted its holdings in shares of argenex by 21.7% in the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company's stock worth $55,744,000 after acquiring an additional 13,606 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

About argenex

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.